- In UC, duvakitug maintained high rates of clinical remission, clinical response, and endoscopic improvement at Week 44
- In CD, duvakitug maintained high rates of endoscopic response, clinical response, and clinical remission at Week 44
- Duvakitug was well tolerated and safety was consistent with the induction study
PARSIPPANY, N.J. and PARIS, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Sanofi announced new positive data from the RELIEVE UCCD phase 2b long-term extension (LTE) study (clinical trial identifier: NCT05668013) in patients with moderately-to-severely active ulcerative colitis (UC) or Crohn’s disease (CD), which demonstrated that duvakitug maintained clinically meaningful efficacy improvements across multiple endpoints over 44 weeks. Duvakitug is an investigational human monoclonal antibody that targets TL1A, a protein that amplifies inflammation and potentially drives fibrosis in UC and CD.
In addition, biomarker findings that advance the understanding of how duvakitug may impact inflammation and tissue remodeling in inflammatory bowel disease (IBD) were shared. These data were presented today at United European Gastroenterology (UEG) Week 2026 in Barcelona.
The RELIEVE UCCD LTE study evaluated the efficacy, safety, and tolerability of duvakitug through 44 weeks of maintenance treatment after induction in patients with UC and CD, the two most common forms of IBD. Patients (n=130, 72 with UC and 58 with CD) who responded to duvakitug treatment in the 14-week induction study were randomized to receive either duvakitug 450 mg or 900 mg subcutaneously every four weeks (Q4W) for up to 58 weeks of total exposure.